Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Download PDF Copy

Editorial Checklist

Reviewed

Sep 4 2009

Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Thomas Weisel Partners 2009 Healthcare Conference in Boston.

Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will be given on Thursday, September 10, 2009 at 1:30pm EDT in the Blaxton Room of the Four Seasons Hotel.

Source:

http://www.celatorpharma.com

Posted in: Drug Trial News

Comments (0)

Download PDF Copy

Suggested Reading

Food-as-medicine could save billions in healthcare costs—here’s what’s standing in its way

Food-as-medicine could save billions in healthcare costs—here’s what’s standing in its way

Discovery solves 67-year-old biochemical mystery about vitamin B1

Discovery solves 67-year-old biochemical mystery about vitamin B1

Targeted drug zongertinib shows strong results for HER2-mutant lung cancer in clinical trial

Targeted drug zongertinib shows strong results for HER2-mutant lung cancer in clinical trial

Cancer immunotherapy effective across all ages despite immune differences

Cancer immunotherapy effective across all ages despite immune differences

ADHD medications show minimal impact on heart health in large study

ADHD medications show minimal impact on heart health in large study

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Both low and moderate-high intensity exercise could help fight against Alzheimer's

Both low and moderate-high intensity exercise could help fight against Alzheimer's

Blood test for tumor DNA may predict melanoma recurrence

Blood test for tumor DNA may predict melanoma recurrence

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies